Breaking News Instant updates and real-time market news.

EGN

Energen

$73.15

1.76 (2.47%)

, VMW

VMware

$152.24

0.26 (0.17%)

17:00
08/14/18
08/14
17:00
08/14/18
17:00

Icahn Capital adds VMware, Cigna, cuts stake in Herbalife

Carl Icahn's Icahn Capital disclosed in an SEC filing its holdings as of June 30, 2018. Icahn Capital's five new buys for the quarter included by size Energen (EGN), VMware (VMW), AmTrust Financial Services (AFSI), and Cigna (CI). The firm increased its stake in two holdings, including by size Icahn Enterprises (IEP) and Newell Brands (NWL). Icahn reduced stakes in two holdings, namely Herbalife (HLF) and Cheniere Energy (LNG). The firm's top holdings as of June 30 were, by size, Icahn Enterprises, CVR Energy (CVI), Herbalife, Cheniere Energy, and Freeport-McMoRan (FCX).

EGN

Energen

$73.15

1.76 (2.47%)

VMW

VMware

$152.24

0.26 (0.17%)

AFSI

AmTrust

$14.55

0.05 (0.34%)

CI

Cigna

$185.28

3.5 (1.93%)

IEP

Icahn Enterprises

$78.75

1.67 (2.17%)

NWL

Newell Brands

$20.65

0.18 (0.88%)

HLF

Herbalife Nutrition

$57.45

0.78 (1.38%)

LNG

Cheniere Energy

$63.48

-0.13 (-0.20%)

CVI

CVR Energy

$35.84

2.37 (7.08%)

FCX

Freeport McMoRan

$14.80

-0.12 (-0.80%)

  • 23

    Aug

  • 24

    Aug

  • 12

    Sep

  • 01

    Oct

EGN Energen
$73.15

1.76 (2.47%)

07/20/18
WILL
07/20/18
DOWNGRADE
WILL
Hold
Energen downgraded to Hold from Buy at Williams Capital
07/12/18
07/12/18
DOWNGRADE
Target $76

Equal Weight
Energen downgraded to Equal Weight on valuation at Morgan Stanley
As previously reported, Morgan Stanley analyst Drew Venker downgraded Energen to Equal Weight from Overweight citing valuation after the stock's year-to-date outperformance compared to its Permian Basin peers. He lowered his price target on Energen shares to $76 from $93.
07/12/18
MSCO
07/12/18
DOWNGRADE
MSCO
Equal Weight
Energen downgraded to Equal Weight from Overweight at Morgan Stanley
08/08/18
IMPC
08/08/18
DOWNGRADE
Target $74
IMPC
In-Line
Energen downgraded to In-Line from Outperform at Imperial Capital
Imperial Capital analyst Irene Haas downgraded Energen to In-Line with an unchanged price target of $74. The analyst views the company's Q2 results as "strong" but finds the stock fairly valued at current levels.
VMW VMware
$152.24

0.26 (0.17%)

08/13/18
PIPR
08/13/18
NO CHANGE
Target $31
PIPR
Overweight
VMware now formidable long-term competitor to NetScout, says Piper Jaffray
Piper Jaffray analyst James Fish says VMware (VMW) is now a more formidable, long-term competitor to NetScout (NTCT) after it announced the acquisition of Dell-EMC's Service Assurance Suite. The analyst, however, believes the acquisition could create near-term opportunities for NetScout to gain market share. He reiterates an Overweight rating on NetScout shares with a $31 price target.
07/10/18
WELS
07/10/18
NO CHANGE
Target $155
WELS
Market Perform
VMware price target raised to $155 from $135 at Wells Fargo
Wells Fargo analyst Phil Winslow raised his price target for VMware (VMW) to $155 from $135 to account for the one-time special dividend and guidance announced in conjunction with Dell Technologies' acquisition of Class V common stock (DVMT) on July 2, 2018. The analyst reiterates a Market Perform rating on VMware's shares.
07/16/18
BOFA
07/16/18
NO CHANGE
Target $190
BOFA
Buy
VMware price target raised to $190 from $161 at BofA/Merrill
BofA/Merrill analyst Kash Rangan raised his price target on VMware (VMW) to $190 and kept his Buy rating, citing his "increased confidence in sustained mid-teens billings growth" as well as its better operating margins of 32% relative to 24% at competitor Red Hat (RHT). Rangan says that the reverse merger at Dell removes the overhang on VMware shares and should increase its valuation multiple in the long term. The analyst also states that his new valuation on the company implies a multiple of 19-times enterprise value to expected FY19 free cash flow, which is still a 15% discount to Red Hat's 22-times because of its slightly lower billings growth, but adds that VMware is still cheaper than Citrix (CTXS) in spite of its faster revenue growth.
08/13/18
OPCO
08/13/18
NO CHANGE
Target $170
OPCO
Outperform
VMware price target raised to $170 from $165 at Oppenheimer
Oppenheimer analyst Ittai Kidron raised his price target for VMware to $170 from $165, while reiterating an Outperform rating on the shares. Based on his U.S./European channel checks, the analyst sees upside potential to VMware's July-quarter consensus numbers, and expects in-line October-quarter guidance.
AFSI AmTrust
$14.55

0.05 (0.34%)

11/13/17
JMPS
11/13/17
DOWNGRADE
JMPS
Market Perform
AmTrust downgraded to Market Perform from Outperform at JMP Securities
11/13/17
11/13/17
DOWNGRADE

Market Perform
AmTrust downgraded to Market Perform at JMP Securities
As previously reported, JMP Securities analyst Matthew Carletti downgraded AmTrust to Market Perform from Outperform at JMP Securities as he believes the current book value multiple appropriately reflects near-term concerns such as A.M. Best "edging a step closer" to a potential downgrade. He thinks the company is taking correct steps for the longer-term, but that these will need to be proven out over time , he tells investors.
03/01/18
RHCO
03/01/18
DOWNGRADE
RHCO
Hold
AmTrust downgraded to Hold from Buy at SunTrust
SunTrust analyst Mark Hughes downgraded AmTrust to Hold after the company announced an agreement to be acquired by an entity formed by private equity funds managed by Stone Point Capital together with the company's Chairman and CEO.
02/26/18
COMP
02/26/18
DOWNGRADE
COMP
Neutral
AmTrust downgraded to Neutral from Buy at Compass Point
CI Cigna
$185.28

3.5 (1.93%)

08/07/18
LEHM
08/07/18
NO CHANGE
LEHM
Overweight
Cigna shares have upside with deal or no deal, says Barclays
Barclays analyst Steve Valiquette sees upside in shares of Cigna (CI) no matter the outcome of the shareholder vote on August 24 relating to its proposed acquisition of Express Scripts (ESRX). Under a deal break scenario, Cigna should trade at a multiple relatively in-line to diversified peer Anthem (ANTM), implying a fair value of $215, Valiquette tells investors in a research note. If the deal is approved, the analyst sees Cigna shares falling to $180 in the near term. However, his sum-of-the-parts analysis yields a current fair value of $213 per share. As such, the analyst sees upside potential on Cigna in both merger vote scenarios. Valiquette keeps an Overweight rating on the shares.
08/03/18
RHCO
08/03/18
NO CHANGE
Target $244
RHCO
Buy
Cigna price target raised to $244 from $220 at SunTrust
SunTrust analyst David MacDonald raised his price target on Cigna (CI) to $244 and kept his Buy rating after its "strong" Q2 results showed a "sizable" earnings beat across its business lines and lower expected medical cost trends. The analyst also maintains his bullish view on the pending Express Scripts (ESRX) deal, stating that the potential benefits of the combination are underappreciated give the strong momentum of the latter heading into 2019. MacDonald contends that investors' merger related concerns are "misplaced" and also sees Cigna valuation as "compelling".
08/02/18
JPMS
08/02/18
NO CHANGE
JPMS
Overweight
Cigna holders unlikely to vote down Express Scripts deal, says JPMorgan
While Cigna (CI) shares have underperformed peers since the deal for Express Scripts (ESRX) was announced in March, shareholders are unlikely to vote down the transaction, JPMorgan analyst Gary Taylor tells investors in a research note after the Wall Street Journal reported that Carl Icahn has built a stake and will push for voting against the deal. The analyst admits the market is taking a more negative view, as Express Scripts' 16% spread to offer value widened to 25% yesterday. Taylor believes few shareholders have questioned the strategic rational of the merger. He believes, however, that some of Icahn's points could resonate with bears in the near-term. The analyst keeps an Overweight rating on Cigna.
08/02/18
SBSH
08/02/18
NO CHANGE
SBSH
Vote against Express Scripts deal 'somewhat shortsighted,' says Citi
Citi analyst Ralph Giacobbe believes a vote against Cigna's (CI) proposed acquisition of Express Scripts (ESRX), which the Wall Street Journal reported that activist Carl Icahn will push for, could prove "somewhat shortsighted given the changing and evolving healthcare landscape and the integrated offering and cash flow that a combined entity would generate to compete more effectively." The analyst says that regardless of the outcome, he remains positive on Cigna shares. The company's model should continue to drive growth without Express Scripts, and potentially enhance growth with the deal, Giacobbe tells investors in a research note. He keeps a Buy rating on Cigna.
IEP Icahn Enterprises
$78.75

1.67 (2.17%)

03/19/18
JEFF
03/19/18
NO CHANGE
JEFF
Newell Brands agreement with Icahn a win for CEO Polk, says Jefferies
Jefferies analyst Kevin Grundy noted that Newell Brands reached an agreement with activist investor Carl Icahn to appoint five directors nominated by Icahn to the company's board, a board which totals eleven directors. In exchange, Icahn agreed to vote all his shares -- he disclosed a 6.9% stake in Newell -- in favor of Newell's nominees. The firm believes that while this news may come as a surprise, it will lead to the shares trading up, and called it a "big win" for CEO Michael Polk, despite the five seats given up being "a hefty price." Jefferies maintained a Hold rating and $29 price target on Newell shares.
03/19/18
WELS
03/19/18
NO CHANGE
Target $25
WELS
Market Perform
Newell Brands agreement with Icahn lends credibility to management plan, says Wells Fargo
Wells Fargo analyst Bonnie Herzog says Newell Brands (NWL) agreement with Carl Icahn, Chairman of Icahn Enterprises (IEP), lends credibility to the management's plan, and likely increases the odds that the former will ultimately prevail in its proxy battle with Starboard. That said, the analyst believes that ongoing fundamental headwinds, the stepped-up divestiture program and organizational disruption likely leaves an overhang on the shares, despite a cheap valuation. Herzog reiterates a Market Perform rating and $25 price target on Newell's shares.
NWL Newell Brands
$20.65

0.18 (0.88%)

04/17/18
04/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Hold from Sell at Pivotal Research with analyst Brian Wieser saying the company "has a lot of positive elements" heading into the back half of the year, including a strong film slate, the launch of new direct to consumer over-the-top services, and efforts in support of the close of the Fox (FOXA) transaction. 2. Coca-Cola (KO) upgraded to Neutral from Sell at Goldman Sachs with analyst Judy Hong saying she sees an improving organic sales growth outlook, "cleaner base" post-refranchising, and better visibility on its margin and earnings targets. 3. Merck (MRK) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying the Keytruda+chemo combination showed better than expected results in lung cancer, boosting the company's immuno-oncology lead against Bristol-Myers (BMY). 4. Newell Brands (NWL) upgraded to Outperform from Market Perform at Wells Fargo with analyst Bonnie Herzog saying the stock's setup is good looking forward, with greater potential upside than downside risk over the next 12 months. 5. Twitter (TWTR) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Brian Nowak citing recent advertiser conversations that have continued to be incrementally positive about Twitter's ad business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/18
WELS
04/17/18
UPGRADE
Target $33
WELS
Outperform
Newell Brands upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Bonnie Herzog upgraded Newell Brands to Outperform and raised her price target for the shares to $33 from $25. The stock's setup is good looking forward, with greater potential upside than downside risk over the next 12 months, Herzog tells investors in a research note. She calls her upgrade more of an event-driven break-up call versus a fundamental improvement call. The analyst's break-up analysis suggests the targeted $10B after-tax proceeds from the planned divestitures could prove conservative. Newell's current valuation is not reflective of its underlying value, Herzog contends.
08/09/18
SBSH
08/09/18
NO CHANGE
SBSH
Buy
Newell Brands selloff this week bit of an overreaction, says Citi
Citi analyst Wendy Nicholson believes the 22% selloff in shares of Newell Brands since Monday's Q2 results "seems like a bit of an overreaction." The quarter largely came in as expected, though a lower tax rate and share count offset weaker profit margins, Nicholson tells investors in a research note. She says what matters most right now is Newell's asset sales. The analyst keeps a Buy rating on the shares.
08/07/18
DBAB
08/07/18
NO CHANGE
Target $23
DBAB
Hold
Newell Brands price target lowered to $23 from $29 at Deutsche Bank
Deutsche Bank analyst Steve Powers lowered his price target for Newell Brands to $23 and keeps a Hold rating on the shares. The analyst views yesterday's 14% selloff post-earnings selloff as warranted. Newell's confidence around its ability to offset the negative impact of tariffs via pricing seems "somewhat uncertain," Powers tells investors in a research note.
HLF Herbalife Nutrition
$57.45

0.78 (1.38%)

03/06/18
03/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Buy from Hold at Stifel with analyst David Ross saying after the recent share pullback, UPS' valuation is "reasonable" considering the risks ahead and the increased capital investments expected over the next several years. 2. PPL Corp. (PPL) upgraded to Outperform from Sector Perform at RBC Capital with analyst Shelby Tucker saying he believes that the uncertainty around the impact of RIIO-2 price controls on the company's financials has been more than discounted in the stock price, while the equity needs due to tax reform have also been digested by investors. 3. First Republic (FRC) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Keating saying he believes the impact of First Republic's "millennial strategies" on client household acquisition is underappreciated and that tax reform will not weigh the bank's businesses. 4. Herbalife Nutrition (HLF) upgraded to Buy from Neutral at Citi with analyst Beth Kite saying since January, the company has made capital allocation announcements, enacted several executive changes, and found out that Bill Ackman closed out his long-standing and well-publicized short position. 5. Mylan (MYL) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/06/18
SBSH
03/06/18
UPGRADE
Target $114
SBSH
Buy
Citi sees further upside in Herbalife, upgrades shares to Buy
Citi analyst Beth Kite last night upgraded Herbalife to Buy from Neutral and raised her price target for the shares to $114 from $85. The stock in premarket trading is up 3%, or $2.98, to $97.25. Since January, the company has made capital allocation announcements, enacted several executive changes, and found out that Bill Ackman closed out his long-standing and well-publicized short position, Kite tells investors in a research note. The analyst sees further upside in the shares as Herbalife executes a tender offer and refinances its debt, to both reinvest in the business and repurchase shares in 2019. If the company can deliver its local currency sales growth guidance in 2018, it would be one of the best top line stories in Household/Personal Care Products, Kite contends.
03/05/18
SBSH
03/05/18
UPGRADE
SBSH
Buy
Herbalife Nutrition upgraded to Buy from Neutral at Citi
05/04/18
RHCO
05/04/18
NO CHANGE
Target $105
RHCO
Hold
Herbalife Nutrition price target raised to $105 from $76 at SunTrust
SunTrust analyst Michael Swartz raised his price target on Herbalife to $105 following its Q1 earnings beat that also showed "improving trends in the U.S." The analyst notes however that China volume fell dramatically by 23% after last year's price increase. Swartz keeps his Hold rating on Herbalife and recommends that investors don't chase the stock price after its year-to-date gains.
LNG Cheniere Energy
$63.48

-0.13 (-0.20%)

07/05/18
LEHM
07/05/18
NO CHANGE
Target $77
LEHM
Overweight
Cheniere Energy price target raised to $77 from $65 at Barclays
Barclays analyst Christine Cho raised her price target for Cheniere Energy (LNG) to $77 and keeps an Overweight rating on the shares. She also raised her price target for Equal Weight-rated Cheniere Energy Partners (CQP) to $38 from $35 and Equal Weight-rated Cheniere Energy Partners LP (CQH) to $37 from $32. Cho estimates the combination of Train 6 and Cheniere Energy Partners' buy-in will add $440 in discounted cash flow to Cheniere Energy on a pre-tax basis. At a 7.5% discounted cash flow yield, the analyst estimates this equates to about $20 per Cheniere Energy share on an undiscounted basis. She thinks the stock could trade to $100 as 2024 approaches, all else being equal.
03/27/18
03/27/18
UPGRADE
Target $63

Outperform
Cheniere Energy upgraded to Outperform at Bernstein
As previously reported, Bernstein analyst Jean Ann Salisbury upgraded Cheniere Energy to Outperform from Market Perform as lower gas price drives better margins on marketing, and an improved discount rate as US LNG should be the lowest cost supply and thus unlikely to be reneged on. The analyst also raised her price target on the shares to $63 from $55.
03/26/18
BERN
03/26/18
UPGRADE
BERN
Outperform
Cheniere Energy upgraded to Outperform from Market Perform at Bernstein
03/15/18
03/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Radian Group (RDN) initiated with a Neutral at Macquarie. 2. Cheniere Energy (LNG) initiated with a Buy at BofA/Merrill. 3. Avid Bioservices (CDMO) initiated with an Outperform at Wells Fargo. 4. Quintana Energy Services (QES) initiated with an Overweight at Capital One. 5. II-VI (IIVI) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CVI CVR Energy
$35.84

2.37 (7.08%)

05/30/18
SBSH
05/30/18
DOWNGRADE
Target $25
SBSH
Neutral
CVR Refining downgraded to Neutral from Buy at Citi
Citi analyst Prashant Rao downgraded CVR Refining (CVRR) to Neutral while raising his price target for the shares to $25 from $22. The exchange offer by CVR Energy (CVI) for CVR Refining units brings the two entities closer to a merger, Rao tells investors in a research note. The analyst no longer sees "compelling enough" upside to justify a Buy rating on CVR Refining.
FCX Freeport McMoRan
$14.80

-0.12 (-0.80%)

08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
08/02/18
08/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Outperform from Perform at Oppenheimer with analyst Colin Rusch saying gross margin performance on the Model 3 will carry the stock over the next 12-plus months. 2. Freeport McMoRan (FCX) upgraded to Neutral from Underperform at BofA/Merrill with analyst Timna Tanners citing valuation, reduced political risk at Grasberg, and a more constructive view on copper. 3. EnLink Midstream Partners (ENLK) upgraded to Buy from Hold at Stifel with analyst Timothy Howard citing the company's Q2 results that topped his expectations and raised 2018 guidance, which also lifted expectations in 2019. 4. Univar (UNVR) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Roert Koort saying the weakness following the in line Q2 report and reaffirmed 2018 guidance is "unwarranted." 5. Qorvo (QRVO) upgraded to Hold from Sell at Summit Insights with analyst Kinngai Chan citing the Q2 report saying investor expectations were high going into the report and now expects shares to perform in-line. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/02/18
BOFA
08/02/18
UPGRADE
Target $17
BOFA
Neutral
Freeport McMoRan upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Timna Tanners upgraded Freeport McMoRan to Neutral from Underperform and maintained a $17 price target citing valuation, reduced political risk at Grasberg, and a more constructive view on copper.
07/26/18
07/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dana (DAN) upgraded to Overweight from Equal Weight at Barclays with analyst Brian Johnson citing the company's Q2 results. 2. Xilinx (XLNX) upgraded to Buy from Neutral at Rosenblatt and to Buy from Underperform at BofA/Merrill. 3. Freeport McMoRan (FCX) upgraded to Hold from Sell at Deutsche Bank with analyst Chris Terry saying he believes the risks are now priced into the shares. 4. Integra LifeSciences (IART) upgraded to Buy from Neutral at BTIG with analyst Ryan Zimmerman saying the pullback in the stock price after its in-line Q2 results has created a more attractive valuation. 5. Cracker Barrel (CBRL) upgraded to Buy from Hold at Maxim with analyst Stephen Anderson saying he sees more stable comps and lower food costs helping the company return to low-teen earnings growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

JOUT

Johnson Outdoors

$93.55

-0.41 (-0.44%)

05:30
09/26/18
09/26
05:30
09/26/18
05:30
Hot Stocks
Johnson Outdoors raises quarterly cash dividend to 14c per Class A share »

Johnson Outdoors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICLK

iClick Interactive Asia

$4.19

-0.1 (-2.33%)

, CTRP

Ctrip

$37.63

-0.645 (-1.69%)

05:28
09/26/18
09/26
05:28
09/26/18
05:28
Hot Stocks
iClick Interactive Asia enters collaboration with Ctrip »

iClick Interactive Asia…

ICLK

iClick Interactive Asia

$4.19

-0.1 (-2.33%)

CTRP

Ctrip

$37.63

-0.645 (-1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDAP

EDAP TMS

$2.99

0.075 (2.57%)

05:26
09/26/18
09/26
05:26
09/26/18
05:26
Hot Stocks
EDAP TMS announces results of HIFU study by Houston Methodist Medical Center »

EDAP TMS announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHEF

Chefs' Warehouse

$37.70

(0.00%)

05:25
09/26/18
09/26
05:25
09/26/18
05:25
Downgrade
Chefs' Warehouse rating change  »

Chefs' Warehouse…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMN

Omnova Solutions

$10.25

0.25 (2.50%)

05:25
09/26/18
09/26
05:25
09/26/18
05:25
Hot Stocks
Omnova Solutions acquires Resiquimica, terms not disclosed »

Omnova Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 13

    Nov

BFRA

Biofrontera

$13.82

(0.00%)

05:23
09/26/18
09/26
05:23
09/26/18
05:23
Hot Stocks
Biofrontera starts patient recruitment for U.S. Phase III trial of Ameluz »

Biofrontera AG announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

FCFS

First Cash Financial

$83.03

0.625 (0.76%)

05:22
09/26/18
09/26
05:22
09/26/18
05:22
Initiation
First Cash Financial initiated  »

First Cash Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 06

    Nov

TFX

Teleflex

$270.60

1.69 (0.63%)

05:21
09/26/18
09/26
05:21
09/26/18
05:21
Hot Stocks
NeoTract announces results from 5 real-world studies of UroLift System »

NeoTract, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

  • 08

    Nov

SONC

Sonic

$43.46

6.85 (18.71%)

05:21
09/26/18
09/26
05:21
09/26/18
05:21
Upgrade
Sonic rating change  »

Sonic upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

TFX

Teleflex

$270.60

1.69 (0.63%)

05:19
09/26/18
09/26
05:19
09/26/18
05:19
Hot Stocks
NeoTract announces results of 2 studies of novel UroLift System »

NeoTract, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

  • 08

    Nov

ICAGY

IAG

$0.00

(0.00%)

05:18
09/26/18
09/26
05:18
09/26/18
05:18
Downgrade
IAG rating change  »

IAG downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$32.55

0.79 (2.49%)

05:17
09/26/18
09/26
05:17
09/26/18
05:17
Hot Stocks
TechnipFMC signs strategic collaboration agreement with Equinor »

TechnipFMC has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 25

    Oct

AMZN

Amazon.com

$1,974.50

40 (2.07%)

05:17
09/26/18
09/26
05:17
09/26/18
05:17
Hot Stocks
Amazon expands grocery delivery, pickup from Whole Foods to more cities »

Amazon and Whole Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 04

    Oct

INO

Inovio

$5.05

0.22 (4.55%)

05:14
09/26/18
09/26
05:14
09/26/18
05:14
Recommendations
Inovio analyst commentary  »

Piper remains buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ATVI

Activision Blizzard

$80.50

-0.11 (-0.14%)

05:11
09/26/18
09/26
05:11
09/26/18
05:11
Recommendations
Activision Blizzard analyst commentary  »

Activision Blizzard price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

05:09
09/26/18
09/26
05:09
09/26/18
05:09
Recommendations
TNDM analyst commentary  »

Tandem Diabetes price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

LOXO

Loxo Oncology

$166.80

3.73 (2.29%)

, BPMC

Blueprint Medicines

$75.20

3.64 (5.09%)

05:06
09/26/18
09/26
05:06
09/26/18
05:06
Recommendations
Loxo Oncology, Blueprint Medicines analyst commentary  »

Loxo RET inhibitor still…

LOXO

Loxo Oncology

$166.80

3.73 (2.29%)

BPMC

Blueprint Medicines

$75.20

3.64 (5.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Nov

  • 27

    Nov

MTB

M&T Bank

$168.53

-1.6 (-0.94%)

05:02
09/26/18
09/26
05:02
09/26/18
05:02
Upgrade
M&T Bank rating change  »

M&T Bank upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STM

STMicroelectronics

$19.10

0.07 (0.37%)

04:59
09/26/18
09/26
04:59
09/26/18
04:59
Upgrade
STMicroelectronics rating change  »

STMicroelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$32.48

-0.11 (-0.34%)

, VIA

Viacom

$34.80

0.05 (0.14%)

04:55
09/26/18
09/26
04:55
09/26/18
04:55
Upgrade
Viacom, Viacom, CBS rating change  »

Viacom upgraded to Buy…

VIAB

Viacom

$32.48

-0.11 (-0.34%)

VIA

Viacom

$34.80

0.05 (0.14%)

CBS

CBS

$56.54

-0.07 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

XOXO

XO Group

$34.91

7.29 (26.39%)

04:55
09/26/18
09/26
04:55
09/26/18
04:55
Downgrade
XO Group rating change  »

XO Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

$18.58

-0.31 (-1.64%)

04:55
09/26/18
09/26
04:55
09/26/18
04:55
Conference/Events
Marvell management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 08

    Oct

04:55
09/26/18
09/26
04:55
09/26/18
04:55
General news
Breaking General news story  »

FOMC Forecasts to be…

EOG

EOG Resources

$125.67

1.675 (1.35%)

, WFT

Weatherford

$2.73

0.035 (1.30%)

04:55
09/26/18
09/26
04:55
09/26/18
04:55
Conference/Events
Credit Suisse to hold a non tour »

4th Annual Oil & Gas…

EOG

EOG Resources

$125.67

1.675 (1.35%)

WFT

Weatherford

$2.73

0.035 (1.30%)

OXY

Occidental Petroleum

$81.31

0.57 (0.71%)

COG

Cabot Oil & Gas

$23.24

0.035 (0.15%)

NFX

Newfield Exploration

$29.24

-0.52 (-1.75%)

FRAC

Keane Group

$12.86

0.27 (2.14%)

MRO

Marathon Oil

$22.50

0.17 (0.76%)

MUR

Murphy Oil

$32.55

-0.21 (-0.64%)

SLB

Schlumberger

$62.54

0.955 (1.55%)

APC

Anadarko

$66.83

0.82 (1.24%)

NOV

National Oilwell

$43.44

-0.04 (-0.09%)

RIG

Transocean

$13.98

0.19 (1.38%)

HES

Hess Corp.

$71.61

-0.41 (-0.57%)

NBR

Nabors Industries

$6.14

-0.085 (-1.37%)

OAS

Oasis Petroleum

$13.92

0.26 (1.90%)

COP

ConocoPhillips

$78.11

1.05 (1.36%)

APA

Apache

$47.78

0.29 (0.61%)

BHGE

Baker Hughes

$33.48

0.64 (1.95%)

HA

Hawaiian Holdings

$38.75

-0.35 (-0.90%)

CVX

Chevron

$123.38

0.72 (0.59%)

FTI

TechnipFMC

$32.55

0.79 (2.49%)

HAL

Halliburton

$41.36

0.28 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 29

    Sep

  • 01

    Oct

  • 04

    Oct

  • 05

    Oct

  • 19

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 29

    Oct

  • 02

    Nov

FBP

First BanCorp

$9.01

0.085 (0.95%)

04:55
09/26/18
09/26
04:55
09/26/18
04:55
Conference/Events
First BanCorp management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

  • 25

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.